New scanner could cut prostate cancer scans in half
NCT ID NCT05470699
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether a new PET-CT scanner (RefleXion RMRS) can produce clear images of prostate cancer using a standard radioactive tracer. About 34 patients will receive both the standard scan and the new scan. If the new scanner works well, it may allow imaging and radiation planning in one session, reducing the number of visits.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fluorine F 18 Piflufolastat (18F-DCFPyL)
- What this could lead to
- If successful, this could allow prostate cancer patients to have imaging and radiation planning in a single session, reducing scan burden.
- What could go wrong
- This is a small, early-stage imaging study (34 participants) focused on technical performance, not treatment outcomes. The new scanner may not match standard imaging quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Shockwaves may speed up erectile recovery after prostate cancer surgery
- Could a common blood pressure drug help fight prostate cancer?
- Can brain waves predict bladder control after prostate surgery?
- New PET tracer could reveal hidden prostate cancer
- New PET-MRI tracer could sharpen prostate cancer biopsy accuracy
- New PET tracer could spot cancers that standard scans overlook